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Background: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse
deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to
depict interstitial fibrosis. We hypothesized that with T1 mapping, which is employed to determine the myocardial
extracellular volume fraction (ECV), can detect diffuse interstitial fibrosis in HCM patients.
Methods: T1 mapping with a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence was used to calculate
ECV in manifest HCM (n = 16) patients and in healthy controls (n = 14). ECV was determined in areas where focal fibrosis
was excluded with LGE.
Results: The total group of HCM patients showed no significant changes in mean ECV values with respect to controls
(0.26 ± 0.03 vs 0.26 ± 0.02, p = 0.83). Besides, ECV in LGE positive HCM patients was comparable with LGE negative HCM
patients (0.27 ± 0.03 vs 0.25 ± 0.03, p = 0.12).
Conclusions: This study showed that HCM patients have a similar ECV (e.g. interstitial fibrosis) in myocardium without
LGE as healthy controls. Therefore, the additional clinical value of T1 mapping in HCM seems limited, but future larger
studies are needed to establish the clinical and prognostic potential of this new technique within HCM.
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Hypertrophic cardiomyopathy (HCM) is a genetic heart
disease, characterized by unexplained left ventricular
(LV) hypertrophy, often accompanied by myocardial
fibrosis [1]. Post-mortem studies revealed that fibrosis
is either present as focal scarring, or diffusely by inter-
cellular deposition of collagen fibers [2]. Histology re-
vealed increased amounts of fibrous tissue not solely in
the interventricular septum, but also in the LV free wall
and even in the right ventricle [3]. However, pathology
studies reported inconsistent quantities of interstitial
fibrosis, most likely as a result of differences in staining
techniques and the heterogeneous nature of HCM [3-5].* Correspondence: w.brouwer@vumc.nl
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reproduction in any medium, provided the orIn-vivo, focal fibrosis can be assessed non-invasively with
cardiovascular magnetic resonance late gadolinium en-
hancement imaging (CMR-LGE) [6]. This technique
however is limited by its reliance on relative differences
of gadolinium (Gd) uptake, assuming that areas with
the lowest concentration of Gd consist of normal myo-
cardium. T1 mapping on the other hand is a CMR tech-
nique that allows absolute T1 value measurements in
any region of the myocardium, enabling the calculation of
the myocardial extracellular volume fraction (ECV), which
represents the amount of interstitial fibrosis [7,8]. We
hypothesized that non-enhanced regions in manifest HCM
contain interstitial fibrosis that remain undetected by
current LGE imaging. Therefore, we applied T1 mapping
before and after contrast administration to calculate ECV
in these non-enhanced regions. ECV values were com-
pared to those in healthy controls.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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HCM patients
The study was approved by the institutional research
ethics board and written informed consent was obtained
from all study participants. Patients were included in the
study when they showed a LV wall thickness (WT) ≥15 mm
as assessed with CMR in the absence of conditions associ-
ated with increased loading of the heart [9]. HCM mutation
analysis was performed in a subset of patients, according to
standard sequencing schemes. Exclusion criteria were a
history of coronary artery disease (CAD) and any contra-
indication for CMR such as an implanted pacemaker or
internal cardioverter defibrillator (ICD) or claustrophobia.
Healthy controls
The subjects in the control group were either healthy
volunteers or genotype negative family members of index
HCM patients, without a history of CAD, valve disease or
hypertension.
CMR acquisition
CMR studies were performed on a 1.5 Tesla whole body
MRI system (Magnetom, Avanto, Siemens, Erlangen,
Germany). First, standard scouts were obtained, followed
by long axis and short axis cine images using a retrospect-
ive gated, steady state free precession (SSFP) gradient echo
sequence. In vivo T1 mapping was performed at a mid-
ventricular short axis slice before, ~8 minutes and ~20 mi-
nutes after the infusion of a bolus (0.2 mmol/kg) of
gadolinium-diethylene triamine pentaacetic acid (Gd-
DTPA) (Magnevist, Scheringen, Berlin, Germany) or gado-
terate meglumine (Gd-DOTA) (Dotarem, Guerbet, Roissy
CdG, France). Both agents are paramagnetic contrast
agents with a similar extracellular distribution and a similar
R1 relaxivity [10]. A single breath-hold, modified Look-
Locker Inversion Recovery (MOLLI) pulse sequence with
ECG-gating was applied to determine absolute T1 values of
the myocardium at all three time points. Eleven images
with various inversion delays were obtained with a 3-3-5
scheme within 17 heart beats [11]. LGE-imaging with full
LV coverage was performed approximately ten minutes
after gadolinium infusion, using an inversion recovery
spoiled gradient echo sequence with magnitude image
reconstruction. Images were corrected for surface coil inho-
mogeneities by a PD-weighted 3D prescan as implemented
in the standard software. The inversion time was set to null
the CMR signal of normal appearing myocardial tissue,
typically at 250 ms. Slice positions of mid-ventricular T1
mapping images and corresponding mid-ventricular LGE
images were identical.
Offline LV and LGE-analysis
Left ventricular mass was calculated by manual delinea-
tion of endocardial and epicardial borders at the end-diastolic phase on all short axis slices and was indexed
for body surface area (BSA). LGE-images were visually
scored on the presence of focal fibrosis. When no focal
fibrosis was present, the entire myocardial short axis
area of the corresponding T1 map was selected to deter-
mine the average myocardial T1 value.
When focal fibrosis was present (LGE-positive), areas of
non-enhanced myocardial tissue were selected. A thresh-
old algorithm was applied on the magnitude LGE images
to select myocardium with a signal intensity (SI) <20% of
maximal SI at the core area of focal fibrosis. Normally, a
50% threshold is applied to select enhanced myocardial
tissue, a full width half maximum (FWHM) algorithm
[12]. To ensure the selection of clear non-enhanced tissue,
a <20% threshold was applied. In these regions of non-
enhanced myocardium, a region of interest (ROI) was
drawn on the corresponding T1 map to determine T1
values. When LGE was present on a different level than
the mid-ventricular T1 mapping slice, signal intensities
of these LGE-positive areas were used to set the thresh-
old for the mid-ventricular LGE slice. Dedicated soft-
ware was used for this analysis (Mass, Medis, Leiden,
the Netherlands).
T1 mapping analysis and ECV calculation
Offline T1 maps were calculated from the MOLLI images
[13] with manual motion correction when deemed neces-
sary [14]. ROI’s were drawn in non-enhanced myocardium
in LGE images and an additional ROI was placed at the
center of the LV blood pool, as shown in Figure 1. These
ROI’s were copied to corresponding T1 maps for all exper-
iments. Relaxation rates (R1 = 1/T1) were calculated for
myocardium and blood pool for both pre-contrast and
post-contrast T1 mapping experiments. Subsequently, the
myocardial partition-coefficient of the contrast agent was
calculated by least-squares linear regression of myocardial
R1 values versus blood pool R1 values over the 3 time
points assuming a dynamic equilibrium of contrast con-
centration between blood and extracellular space [15].
Finally, ECV, reflecting the amount of interstitial fibrosis,
was calculated using a correction for blood hematocrit
[7,15]. In all subjects, hematocrit values were obtained
immediately before or after the CMR acquisition.
To demonstrate that T1 mapping discriminates ad-
equately areas of clear enhancement, intermediate en-
hancement and no enhancement, ECV was determined in
LGE-positive HCM patients in areas with focal fibrosis (SI
of LGE >50% of maximum, equal to the FWHM algo-
rithm), within an area of intermediate SI (>20% and <50%
of maximum SI) and within an area of non-enhanced
myocardium (see Figure 1).
In subjects with no focal fibrosis, also a segmental ana-
lysis of the T1 maps and subsequent ECV was performed
using 6 segments (inferoseptal, anteroseptal, anterior,
Figure 1 The selection of myocardial regions with different signal intensities in a LGE-positive HCM patient. Image A represents a short
axis LGE image of a HCM patient, showing extensive focal fibrosis in the myocardium (white areas). The maximum signal (max SI) was determined by
drawing a small ROI in the core of the region with focal fibrosis. Image B, which is the identical CMR image as (A) but with a segmentation overlay,
shows non-enhanced myocardium (SI <20% max SI), intermediate enhanced myocardium in yellow (>20 and <50% of max SI) and enhanced
myocardium in red (SI >50% of max SI) using the thresholding algorithm. Image C, D, and E show manually drawn ROI’s on corresponding T1
maps for non-enhanced, intermediate enhanced, and enhanced myocardium, respectively. LGE = late gadolinium enhancement. SI = signal
intensity. ROI = region of interest.
Table 1 Baseline characteristics of HCM patients and
controls
HCM (n = 16) Controls
(n = 14)
p-value
Age (y) 47 ± 14 48 ± 15 0.82
Gender (m/f) 12/4 8/6 0.44
Mutation in
sarcomeric gene
- MYBPC3 (6, 38%)
- MYH7 (1, 6%)
- TNNT2 (2, 13%)
- Excluded (3, 19%) - Excluded (11, 79%)
- Unknown (4, 25%) - Unknown (3, 21%)
Systolic BP
(mmHg)
132 ± 12 132 ± 26 0.96
Diastolic BP
(mmHg)
75 ± 11 77 ± 9 0.67
Heart rate (BPM) 63 ± 13 68 ± 10 0.21
BSA (kg/m2) 2.0 ± 0.17 1.9 ± 0.19 0.10
Medication Beta-blocker (8, 50%) None
Ca-antagonist (1, 6%)
Hematocrit (L/L) 0.45 ± 0.04. 0.42 ± 0.02 0.007
MYBPC3, MYH7 and TNNT2 genes encoding the sarcomeric proteins myosin
binding protein C, myosin heavy chain and troponin T, respectively. BP = blood
pressure. BPM = beats per minute. BSA = body surface area.
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17-segment model of the American Heart Association
(AHA) [16].
Statistical analysis
All statistical analyses were performed in SPSS version
15.0 (SPSS Inc., Chicago, IL, USA).
Data are expressed as mean ± standard deviation (SD).
Continuous data were compared using a two-sided Stu-
dent’s t-test or non-parametric tests when appropriate.
For multiple comparisons, analysis of variance (ANOVA)
with Bonferroni correction was used. Proportions were
compared using a Chi-square test. Univariate regression
analysis was performed to evaluate the relation of age,
gender, and the presence of LGE with ECV. Factors that
showed a significant association in this univariate ana-
lysis were subsequently evaluated in a multivariate linear
regression analysis. Mutation status was not evaluated in
the model, since not all HCM patients underwent prior




In total 20 HCM patients were included in the study,
with a mean age of 50 ± 14 years and 80% male. As a
result of a medical history of hypertension, 4 out of 20
HCM patients were excluded from the primary analysis.
The remaining 16 HCM patients were predominantly male
(n = 12) with mean age 47 ± 14 years. Fourteen healthy sub-
jects served as controls (8 male, mean age 48 ± 15 years).
Baseline characteristics of HCM patients and controls
are outlined in Table 1. Both groups were comparable
regarding age and gender. As shown, the majority
of HCM patients had mutation positive status and
received cardiac medication. Blood hematocrit (L/L)levels were significantly higher in HCM compared to
controls (0.45 ± 0.04 vs 0.42 ± 0.02, p = 0.007).
CMR findings
Mean indexed LV mass in HCM patients was 83 ± 37 g/m2
and mean maximal LV wall thickness was 18 ± 3 mm. Nine
(56%) HCM patients showed areas of focal fibrosis, of
which eight displayed enhancement at the mid-ventricular
LGE image. The remaining patient showed regional
contrast enhancement at LV regions that were non-

































Figure 3 Extracellular volume fraction (ECV) values in non-
enhanced myocardium in HCM patients and controls. The group
of HCM patients is subdivided into patients with focal fibrosis on
LGE (HCM-LGE+) and without focal fibrosis (HCM-LGE-). Notice that
solely the group of ‘hypertensive HCM’ patients shows a significantly
higher ECV compared to the other groups. ECV = extracellular
volume fraction. HCM = hypertrophic cardiomyopathy. LGE = late
gadolinium enhancement. * p < 0.05.
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heart muscle.
T1 mapping analysis
Motion correction was applied in 9 T1 maps in 6 sub-
jects (4 HCM, 2 controls) to correct for respiratory mo-
tion. Figure 2 shows the ECV values in LGE positive
HCM patients in myocardial regions with SI <20%, SI
20-50% and SI >50%. Regions with SI >50% showed sig-
nificantly higher ECV values with respect to regions
with a SI between 20-50% and regions with a SI <20%
(0.45 ± 0.11.vs 0.35. ± 0.06, p = 0.03 and 0.45 ± 0.11 vs
0.27 ± 0.03, p < 0.001, respectively). Furthermore, myo-
cardium with SI 20-50% on LGE imaging showed a sig-
nificantly higher ECV value than myocardium with a SI
<20% (p = 0.003).
Difference in mean ECV values between groups
Analysis and comparison of ECV values in non-enhanced
myocardium in HCM patients and controls resulted in the
following; no differences were observed in ECV values
between the total group of HCM patients and controls
(0.26 ± 0.03 vs 0.26 ± 0.02, p = 0.83), between LGE positive
HCM patients and controls (0.27 ± 0.03 vs 0.26 ± 0.02,
p = 0.41), and between LGE negative HCM patients and
controls (0.25 ± 0.03 vs 0.26 ± 0.02, p = 0.17). Besides, ECV
differences between LGE positive and LGE negative
HCM patients were non-significant (p = 0.12). Results























Figure 2 ECV values in regions with different myocardial
enhancement at LGE-images in HCM patients with focal fibrosis.
Regions in the core of focal fibrosis (SI >50%), apparent normal
regions (SI <20%), and regions with intermediate enhancement
(SI 20-50%) *p < 0.05, † p < 0.01, § p < 0.001. ECV = Extracellular
volume fraction. SI = signal intensity.Segmental analysis of ECV
Within HCM patients without LGE, ANOVA analysis
with Bonferroni correction revealed no significant differ-
ences in ECV between segments (p = 0.63). In controls
however, ECV values differed significantly (p = 0.01), with
both inferoseptal and anteroseptal segments containing
highest ECV values (both 0.28 ± 0.02) and anterior and
anterolateral lowest values (both 0.25 ± 0.02). When we
compared corresponding segments of LGE negative HCM
patients and controls, there were no significant differences
in ECV values (see Table 2). When segments containing
ROI’s with SI <20% in LGE positive HCM patients were
included in the segmental analysis, results remained non-
significant (data not shown).
Hypertrophic and non-hypertrophic segments of the left
ventricle
When ECV values between non-enhanced hypertrophic
(LVWT ≥15 mm, n = 8) and non-hypertrophic (LVWT
<15 mm, n = 56) segments were compared in the group
of HCM patients, hypertrophic segments showed sig-
nificantly higher ECV values (0.29 ± 0.03 vs 0.26 ± 0.04,
p = 0.02). Of the 8 hypertrophic segments, 3 were located
at the inferoseptum, 3 at the anteroseptum and 2 anterior.
Factors associated with mean ECV
For the total study population (HCM patients and con-
trols combined, n = 30), age, gender and the presence of
Table 2 Segmental values of myocardial extracellular
volume fraction in HCM LGE negative patients and
controls
ECV per segment HCM-LGE- (n = 7) Controls (n = 14) p-value
Inferoseptal 0.26 ± 0.02 0.28 ± 0.02 0.08
Anteroseptal 0.26 ± 0.03 0.28 ± 0.02 0.09
Anterior 0.25 ± 0.03 0.25 ± 0.02 0.68
Anterolateral 0.24 ± 0.03 0.25 ± 0.02 0.20
Inferolateral 0.24 ± 0.04 0.26 ± 0.02 0.44
Inferior 0.24 ± 0.04 0.27 ± 0.03 0.13
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variate regression analysis (R = 0.22, p = 0.24, R = 0.12,
p = 0.53 and R = 0.25, p = 0.19, respectively). Interest-
ingly, when we added the excluded 4 HCM patients
to the analysis, hypertension was independently and
strongly associated with ECV (R = 0.66, p < 0.001). Off
note, two of these four patients carried a sarcomeric
mutation, one had extreme LVWT (24 mm) and one
patient showed patchy LGE and had a LVWT of 21 mm.
Within the group of HCM patients only, there were no
significant relationships between LV wall thickness and LV
mass with ECV (R = 0.33, p = 0.22 and R = 0.36, p = 0.17).
Also, there was no difference in ECV between genotype
positive HCM patients and HCM patients in whom a
sarcomeric mutation was excluded by genetic analysis
(0.26 ± 0.03 vs 0.24 ± 0.02, p = 0.31).
Discussion
The major outcome of this CMR study using T1 map-
ping was that in hypertrophic cardiomyopathy areas
without late gadolinium enhancement showed a similar
extracellular volume fraction (ECV) compared to con-
trols. This is in line with a study by Ugander et al. [17],
who reported non-elevated ECV in ‘normal appearing’
myocardium in non-ischemic cardiomyopathies. Study
results are not directly comparable however, since the
patient population in present study was defined more
precisely (HCM only) and thresholding was used to
select ROI’s in LGE positive HCM patients instead of
visual interpretation.
The second observation in this study was that besides
comparable global (mean) ECV values, also segmental
ECV values were virtually similar between HCM patients
and controls (see Table 2). Interestingly, in agreement with
the general observation that focal fibrosis typically occurs
in areas with LV hypertrophy, we observed highest ECV
values in hypertrophic LV segments. It must be noted how-
ever that the majority of these segments were located at
the septum, which also showed highest ECV values in
healthy control subjects (Table 2). The ECV value observed
in our control group was similar to values reported in
earlier studies using a similar MOLLI-sequence for T1mapping before and after contrast administration, and the
standard deviation was rather small [18,19].
To demonstrate that absolute T1 measurements reliably
discriminated areas with different signal intensities on
qualitative LGE images in our study, myocardium was
stratified into low, intermediate and high enhancement on
LGE images. Figure 2 demonstrated that the translation
between these quantitative (T1 mapping) and qualitative
(LGE) imaging techniques was valid in differentiating
myocardial tissue with various collagen concentrations.
In this study, we applied ECV assessment after a bolus
of gadolinium, in contrast to Flett et al. [7], who used con-
tinuous contrast infusion to obtain a steady state concen-
tration of contrast agent between myocardium and blood.
Jerosch-Herold et al. [15] showed that a dynamic equilib-
rium of contrast between blood and extracellular space is
reached after a minimum delay of four minutes following
bolus infusion. Such a dynamic equilibrium also allows
ECV assessment, as confirmed by the study of Chow et al.
[20] and White et al. [21]. In this study, a time delay of
about 8 minutes was applied before the first post-contrast
T1 experiment. A clear indication for the presence of a
dynamic equilibrium was the observed linear relation of
R1 values between myocardium and blood over all three
time points (data not shown), without obvious deviation.
In our study, the factors age, gender, and the presence
of LGE showed no significant association with the extra-
cellular volume fraction in non-enhanced myocardium.
The observation that age was non-significant related to
ECV is in line with the study by Ugander et al. [17], in
which only a modest correlation (r = 0.28) was observed in
a larger patient group. We observed no gender-specific
differences in ECV, either on a global or on a segmental
level, in contrast to Sado et al. [18], who found higher
ECV in the septum of women. Although hypertension is a
strict exclusion criterion for the diagnosis HCM [1], we
performed a secondary analysis with four ‘hypertensive
HCM’ patients, of which two had genotypic diagnosis of
HCM and two had a phenotype strongly suggesting HCM
(extreme LVWT and/or ‘patchy’ fibrosis) [1,22]. Hyperten-
sion appeared a strong and independent predictor of ECV,
which is in agreement with a recent study by Coelho-
Filho et al. [23]. They reported also on an elevated ECV
in hypertensive patients compared to healthy controls.
Apparently, increased systemic pressure importantly
contributes to diffuse fibrosis formation of the heart,
possibly irrespective of the underlying condition of the
cardiac muscle involved. Future studies are needed
however to address this issue.
As stated before, the group of HCM patients showed
no differences in ECV in non-enhanced myocardium
with respect to controls. This contradicts studies that
reported increased myocardial collagen synthesis in HCM
[24], which was even seen in a pre-hypertrophic state [25].
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creased deposition of diffuse fibrosis throughout the entire
LV in post-mortem HCM hearts [4,5]. These discrepancies
may be explained by the following; First, T1 mapping
may lack the sensitivity to detect subtle interstitial
changes, which can be visualized with microscopy or
indirectly demonstrated by molecular analysis. Secondly,
the fibrotic burden of the myocardium in our mainly
asymptomatic HCM patients is likely to be less compared
to the explanted hearts of ‘end-stage patients [2-4].Limitations
Since this study was conducted in a relatively low
number of HCM patients and controls, results should
be interpreted with care. Nevertheless, mean ECV in
healthy subjects was comparable with control values
previously reported by other study groups [18,19] and
standard deviations were relatively small, indicating
reliable methodology. The sensitivity of T1 mapping for
motion is known to generate some blurring of images
and therefore decreased reliability of measurements,
since through-plane motion was not corrected for. To
minimize these effects of through-plane motion, we
assessed ECV values in regions without enhancement
with a maximum size. Another limitation of the study is
the use of a single mid ventricular short axis slice for
ECV assessment. Whole heart mapping would have
been preferable since HCM is thought to display (focal)
fibrosis throughout the entire LV. Moreover, two types
of contrast agents were applied in this prospectively
designed study. The subset of control patients in whom
sarcomeric mutations were excluded received Gd-DTPA,
since they also served as controls in another study. In the
remainder of controls and patients, the newer Gd-DOTA
agent was used. The impact on ECV calculation is consid-
ered non-significant however, since the relevant pharmo-
kinetics of both contrast agents are similar, as well as their
relaxivity [10]. The ECV determination is insensitive to
small changes in absolute relaxivity of the agent, as both
blood and tissue T1 values are changed. Finally, a phase
sensitive inversion recovery (PSIR) reconstruction has
been shown superior to magnitude reconstruction in
defining areas in LGE images [26]. However, in our
study optimal nulling and selection of ROI’s using a low
threshold method minimized these subtle effects.Conclusions
This CMR study showed that HCM patients have a simi-
lar extracellular volume fraction, in myocardium without
LGE as healthy controls. The additional clinical value of
T1 mapping in HCM seems therefore limited, but future
larger studies are needed to establish the clinical and
prognostic potential of this new technique within HCM.Abbreviations
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